The mechanisms that are underlying these observations need to be further defined, but they raise the important possibility that the therapeutic enhancement of FoxO1 in PAH may inadvertently contribute to skeletal muscle dysfunction through the direct effects of FoxO1 in skeletal muscle homeostasis. Here, FOXO1 is linked to pulmonary arterial hypertension.